Click here to view the August edition of The Meeting Place
News
The world of life sciences is complex - add insurance requirements into the mix and it can become a very confusing place to be.
Having appropriate insurance and risk management solutions in place can be crucial for any life science business, whether your seeking initial funding, running clinical trials or taking a product to market.
There are many questions that arise – and myths that surround these topics. Here we share some of the most common myths that have been debunked by CFC Underwriting, a specialist insurance provider to the science and technology sectors.
Researchers are invited to apply to receive DNA that has been synthesised using Evonetix’s platform
16th AUGUST 2022
Designed to efficiently induce differentiation in ES and iPS cells, AMSBIO has expanded its iMatrix series of recombinant laminin E8 fragments to now include isoforms LN-111 and LN-332.
This expanded range of laminin isoforms (LN-111, 332, 511, 411 and 221) now provides even greater flexibility and control when tailoring your substrate to the requirements of specific cultured cells.
Cambridge UK: 11 August 2022
Partners& has become the latest partner to join forces with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of the One Nucleus Members, the Partner and One Nucleus in delivering on its core remit of supporting innovation.
AMSBIO offers a range of lentivirus production services to provide tailor-made products to support your research.
Lentiviral vectors are a valuable tool for delivering target genes into most types of dividing and non-dividing mammalian cells in vitro and in vivo. Typically, production of custom lentiviral vectors is a laborious and challenging process, especially when high-titer lentiviral vectors are required. The custom lentiviral vector production service from AMSBO offers researchers a proven partner to avoid this bottleneck and speed up your research.
• Inspira Pharmaceuticals has moved into Stevenage Bioscience Catalyst’s Lab Hotel to develop its IPX enzyme technology
• The Lab Hotel provides free laboratory and office accommodation for start-up companies for six months
• Companies in the Lab Hotel have access to scientific and business support while they develop their innovations and secure their next round of funding.
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR GRANTED EUROPEAN PATENTS PROTECTING PROPRIETARY FORMULATIONS OF
HIGH CONCENTRATION HUMIRA® BIOSIMILAR
- Patents demonstrate strength of innovative ArestatTM technology and its potential in development of enhanced formulations of high value biologics
- Further strengthens Group’s extensive patent portfolio protecting its proprietary Arestat™ technology and proprietary products
Learn to Discover (L2D) is a cutting edge course, specifically targeted at bioscience and medicine professionals, equipping individuals with powerful skills in Python programming, data science, machine learning and aspects of AI, aimed at furthering your research.
Created and delivered by a team of expert research scientists, a rich curriculum of weekly lectures, live webinars, exercises and assignments is paired with one on one tutor guided support.
Cypex’s recombinant xenobiotic metabolizing enzymes complement BioIVT’s extensive portfolio of hepatocytes and related hepatic products for drug research and development
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired Cypex, a renowned manufacturer of recombinant xenobiotic metabolizing enzymes, based in Dundee, Scotland. Cypex’s extensive enzyme portfolio covers a wide range of proteins involved in drug metabolism.